PAIN
Volume 143, Issue 3 , Pages 169-171 , June 2009

Non-steroidal anti-inflammatory drugs for neuropathic pain: How do we explain continued widespread use?

  • Thuong Vo

      Affiliations

    • Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    • ,
  • Andrew S.C. Rice

      Affiliations

    • Department of Anaesthetics, Pain Medicine and Intensive Care, Faculty of Medicine, Imperial College London, London, UK
    • ,
  • Robert H. Dworkin

      Affiliations

    • Departments of Anesthesiology and Neurology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 604, Rochester, NY 14642, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 585 275 3524; fax: +1 585 473 5007.

Received 5 January 2009 ,Revised 13 March 2009 ,Accepted 13 March 2009.

References 

  1. Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153–1169
  2. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5:143–149
  3. Bingham S, Beswick PJ, Bountra C, Brown T, Campbell IB, Chessell IP, et al. The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization. J Pharmacol Exp Ther. 2005;312:1161–1169
  4. Boswell DJ, Ostergaard K, Philipson RS, Hodge RA, Blum D, Brown JC, et al. Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies. Med J Med. 2008;10:259
  5. Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Int Med. 1987;147:1442–1444
  6. DeLeo JA, Colburn RW, Nichols M, Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res. 1996;16:695–700
  7. Dellemijn PLI, Verbiest NBC, van Vliet JJ, Roos PJ, Vecht CJ. Medical therapy of malignant nerve pain: a randomized double-blind explanatory trial with naproxen versus slow-release morphine. Eur J Cancer. 1994;30A:1244–1250
  8. Dieleman JP, Kerklaan J, Huygen FJPM, Bouma PAD, Sturkenboom CJM. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain. 2008;137:681–688
  9. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63:959–965
  10. Dworkin RH, Barbano RL, Tyring SK, Betts RF, McDermott MP, Pennella-Vaughan J, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009;142:209–217
  11. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Jensen TS, Kalso EA, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–251
  12. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients perspectives. J Pain. 2006;7:892–900
  13. Griffin RS, Woolf CJ. Pharmacology of analgesia. In:  Golan DE,  Tashjian AH,  Armstrong EJ,  Armstrong AW editor. Principles of pharmacology: the pathophysiologic basis of drug therapy. Baltimore, MD: Lippincott Williams & Wilkins; 2005;p. 229–246
  14. Hasnie FS, Breuer J, Parker S, Wallace V, Blackbeard J, Lever I, et al. Further characterization of a rat model of varicella zoster virus-associated pain: relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience. 2007;144:1495–1508
  15. Hempenstall K, Nurmikko TJ, Johnson RW, A’Hern RP, Rice ASC. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2:628–644
  16. Kawakami M, Matsumoto T, Hashizume H, Kuribayashi K, Tamaki T. Epidural injection of cyclooxygenase-2 inhibitor attenuates pain-related behavior following application of nucleus pulposus to the nerve root in the rat. J Orthop Res. 2002;20:376–381
  17. Kochar DK, Agarwal RP, Joshi A, Kumawat BL. Herpes zoster and post-herpetic neuralgia: a clinical trial of aspirin in chloroform for anodyne. J Assoc Physicians India. 1998;46:337–340
  18. Kontinen VK, Meert TK. Predictive validity of neuropathic pain models in pharmacological studies with a behavioral outcome in the rat: a systematic review. In: Dostrovsky JO, Carr DB, Koltzenburg M, editors. Proceedings of the 10th World Congress on Pain. Seattle, WA: IASP Press; 2003. p. 489–98.
  19. Ma W, Du W, Eisenach JC. Role of both spinal cord COX-1 and COX-2 in maintenance of mechanical hypersensitivity following peripheral nerve injury. Brain Res. 2002;937:94–99
  20. Ma W, Eisenach JC. Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci. 2002;15:1037–1047
  21. Max MB, Schafer SC, Culnane M, Dubner R, Gracely RH. Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther. 1988;43:363–371
  22. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain. 2006;10:127–135
  23. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain: consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12:13–21
  24. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356–363
  25. Shackelford S, Rauck R, Quessy SN, Blum D, Hodge RA, Philipson RS. A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381 in patients with postherpetic neuralgia. J Pain, in press.
  26. Syriatowicz JP, Hu D, Walker JS, Tracey DJ. Hyperalgesia due to nerve injury: role of prostaglandins. Neuroscience. 1999;94:587–594
  27. Takahashi M, Kawaguchi M, Shimada K, Konishi N, Furuya H, Nakashima T. Peri-sciatic administration of indomethacin early after nerve injury can attenuate the development of tactile allodynia in a rat model of L5 single spinal nerve injury. Neurosci Lett. 2004;356:37–40
  28. Wallace VCJ, Blackbeard J, Pheby T, Segerdahl AR, Davies M, Hasnie F, et al. Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain. 2007;133:47–63
  29. Weber H, Holme I, Amlie E. The natural course of acute sciatica with nerve root symptoms in a double-blind placebo-controlled trial evaluating the effect of piroxicam. Spine. 1993;18:1433–1438
  30. Zhao FY, Spanswick D, Martindale JC, Reeve AJ, Chessell IP. GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury. Pain. 2007;128:78–87
  31. Zhao Z, Chen SR, Eisenach JC, Busija DW, Pan HL. Spinal cyclooxygenase-2 is involved in development of allodynia after nerve injury in rats. Neuroscience. 2000;97:743–748

PII: S0304-3959(09)00163-8

doi: 10.1016/j.pain.2009.03.013

PAIN
Volume 143, Issue 3 , Pages 169-171 , June 2009

Article Tools